Differences in small airways disease between asymptomatic and symptomatic subjects with airway hyperresponsiveness

Completed

• Conditions: asthma; oversensitive airways; 10006436

• Registration Number: NL-OMON37837
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 45

Inclusion Criteria

Inclusion criteria for asymptomatic subjects without AHR :
• Age between 18 and 65 years.
• FEV1 > 80% predicted post bronchodilator.
• PC20 methacholine <= 8 mg/ml.
• No history of asthma or previous use of asthma medication.;Inclusion criteria for asymptomatic subjects without AHR :
• Age between 18 and 65 years.
• FEV1 > 80% predicted post bronchodilator.
• PC20 methacholine >8 mg/ml.
• No history of asthma or previous use of asthma medication.;Inclusion criteria for patients with asthma:
• Age between 18 and 65 years.
• FEV1 > 80% predicted.
• PC20 methacholine <=8 mg/ml.
• Doctor's diagnosis of asthma
• No history of COPD

Exclusion Criteria

• Use of inhaled or oral steroids, antihistamines, nedocromil, theophylline, leukotrien antagonists or long-acting beta-agonists for at least three weeks before the start of the study.
• Any disease that may affect the outcome of the study as judged by the Investigator.
• FEV1 <1.2 liter.
• A respiratory tract infection within 4 weeks prior to the start of the study.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>peripheral airway resistance, measured with IOS</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Peripheral airway resistance measured with IOS during provocationtest<br /><br><br /><br>Other small airways parameters:<br /><br>- FEF25-75<br /><br>- alveolar NO<br /><br>- RV, RV/TLC<br /><br><br /><br>mRNA expression in nasal epithelium.</p><br>